Most profitable drugmaker? Not a Big Pharma

Which pharma is the most profitable? You might be surprised. A new analysis of net margins by EvaluatePharma tagged companies for profitability, and the winner wasn't one of the biggies. Not Pfizer, not Johnson & Johnson ... but PDL BioPharma. Yep, that little drugmaker that managed a net margin of 68.9 percent in 2008, posting a profit of $203 million for the year.

In fact, when you look at EvaluatePharma's net margin numbers, you'll crawl down below the top five to get to the first Big Pharma. Pfizer came in at seventh with a net margin of 33.9 percent, up 2.5 percentage points from 2007. (Profits for the No. 1 drugmaker by sales amounted to $16.4 billion.) Merck captured ninth place with a net margin of 32.2 percent (and profits of $7.67 billion). Check out the list for more.

- see the list and analysis at Seeking Alpha

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.